Key Points
Dec 13 (Reuters) - Vertex Pharmaceuticals (VRTX.O) said on Wednesday its drug, VX-548, was successful in reducing nerve pain in patients in a mid-stage trial...
Treatment with the drug resulted in a statistically significant reduction in weekly average of daily pain intensity, as measured on a scale at 12 weeks...
The trial studied the non-opioid pain drug in patients with diabetic peripheral neuropathy, a type of nerve damage caused by high blood sugar...
